- Home
- HSAI vs PRAX Comparison
HSAI vs PRAX Comparison
Compare HSAI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSAI | PRAX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HSAI | PRAX |
|---|---|---|
| Price | $22.91 | $294.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $31.58 | ★ $373.79 |
| AVG Volume (30 Days) | ★ 1.6M | 840.2K |
| Earning Date | 11-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $385,835,909.00 | $7,463,000.00 |
| Revenue This Year | $55.36 | N/A |
| Revenue Next Year | $46.30 | $12,467.71 |
| P/E Ratio | $51.38 | ★ N/A |
| Revenue Growth | 43.17 | ★ 364.98 |
| 52 Week Low | $10.41 | $26.70 |
| 52 Week High | $30.85 | $317.72 |
Technical Indicators
Market Signals| Indicator | HSAI | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 67.94 |
| Support Level | $21.90 | $266.51 |
| Resistance Level | $23.08 | $317.72 |
| Average True Range (ATR) | 0.87 | 13.72 |
| MACD | 0.24 | -0.08 |
| Stochastic Oscillator | 78.21 | 64.45 |
Price Performance
Historical ComparisonAbout HSAI Hesai Group each ADS represents one Class B ordinary share
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.